louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04392050: A Community-Based Educational Intervention to Improve Colorectal Cancer Screening
Official title: A Community-Based Educational Intervention to Improve Colorectal Cancer Screening
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Colorectal Carcinoma
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2020-05-18
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Under-represented populations with a focus on African American, Latinx, and Asian (Chinese) in the Sidney Kimmel Cancer Center catchment area

Brief summary: This study investigates the facilitators and barriers to colorectal cancer screening in underserved populations with a focus on African American, Latinx, and Asian (Chinese) in the Sidney Kimmel Cancer Center catchment area. Learning what encourages people and what keeps people from getting colorectal cancer screening may help researchers develop an educational tool for colorectal cancer screening that addresses colorectal cancer knowledge, beliefs, and cultural factors in underserved populations.

Detailed description: PRIMARY OBJECTIVE:

I. Develop a culturally tailored colorectal cancer education intervention for underserved and under-represented populations with a focus on African American, Latinx, and Asian (Chinese) in the Sidney Kimmel Cancer Center catchment area.

OUTLINE:

KEY CONTACT INTERVIEWS: Participants participate an interviews over 60 minutes focusing on identifying facilitators and barriers to colorectal cancer screening, essential cultural factors to include in the educational intervention, and insights into the best use of the National Cancer Institute (NCI)'s Screen to Save materials.

FOCUS GROUPS: Participants attend focus groups over 60-90 minutes to examine and define further facilitators and barriers to colorectal cancer, cancer knowledge and beliefs, essential cultural factors to include in the educational intervention, insights into the best use of the NCI's Screen to Save materials, and identification of factors to consider for dissemination and sustainability.

After completion of study, participants are followed up for up to 12 weeks.

Eligibility criteria: Inclusion Criteria:

* • Focus Groups may be facilitated in Chinese (Mandarin), English, or Spanish depending on participant preference

Exclusion Criteria:

* • Individuals who do not meet the inclusion criteria

  * Individuals who have been diagnosed with colorectal cancer

Primary outcomes:
measure: Successful completion of the key contact interviews and focus groups leading to the development of the culturally tailored educational intervention
timeFrame: Up to 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson University
state: Pennsylvania
Study officials:
affiliation: Thomas Jefferson University
name: Ana Marie Lopez
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02321150: A Novel Technique for the Removal of Pterygiums
Official title: A Novel Technique for the Removal of Pterygiums
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pterygium
Keywords: Pterygium
Pterygiums
Pterygia
Graft
Autograft
Excision
Surgery
Eye
electrocautery
polyglactin
Lead sponsor: The University of The West Indies
Sponsor class: OTHER
First posted: 2014-12-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to introduce a new surgical technique for the removal of pterygiums that entails the use of bipolar electrocautery to secure the graft, rather than sutures.

With this, the objective is to evaluate the benefits of a new technique for pterygium surgery with respect to postoperative patient comfort, surgery time, cost and recurrence rate.


Eligibility criteria: Inclusion Criteria:

* Patients with one or more pterygiums over age 18

Exclusion Criteria:

* Patients with glaucoma

Primary outcomes:
measure: Patient Discomfort
timeFrame: Day 1
measure: Patient Discomfort
timeFrame: Week 1
measure: Patient Discomfort
timeFrame: Week 2
measure: Patient Discomfort
timeFrame: Week 3
measure: Patient Discomfort
timeFrame: Week 7
measure: Patient Discomfort
timeFrame: 3 months
Secondary outcomes:
measure: Operating time
timeFrame: day 1
Other outcomes:
measure: Operating Cost
timeFrame: day 1
measure: Recurrence
timeFrame: 1 year
Locations:
city: Bridgetown
country: Barbados
facility: Queen Elizabeth Hospital
Study officials:
affiliation: The Queen Elizabeth Hospital
name: Kim N Jebodhsingh, MBBS, DABO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05385250: Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II
Official title: Bone-sparing Chemoradiotherapy for Anal Cancer - A Prospective Phase II Trial Danish Anal Cancer Group Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Anal Cancer
Radiotherapy Side Effect
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
Collaborators: name: Herlev Hospital
name: Zealand University Hospital
name: Vejle Hospital
First posted: 2022-05-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A phase II prospective observational clinical trial
Primary purpose: TREATMENT

Brief summary: This study proposal includes a prospective clinical trial of bone sparing treatment planning in anal cancer patients. the trial aim to lower the risk of bone damage, while adhering with the constrains to the bowel, bladder and other conventional Organs At Risk, and finally to describe the fraction of pelvic insufficiency fractures in patients treated with optimized radiotherapy.

Detailed description: Patients will receive standard (chemo)-radiotherapy according to national Danish Anal Cancer Group (DACG) guidelines, but the bone-sparing focus will be added to the algorithm for dose-constrains and planning objectives. A bone specific magnetic resonance scan will be performed at 1 year post treatment. Additional substudies include collection of blood samples for translational research purposes.

Eligibility criteria: Inclusion Criteria:

* Patients with biopsy verified localized squamous cell anal cancer
* Indication for standard (chemo)-radiotherapy with curative intend for anal cancer as per multidisciplinary team decision
* Clinical eligible for standard (chemo)-radiotherapy as per physicians' decision
* Written and oral consent
* Age at least 18 years

Exclusion Criteria:

* Previous pelvic radiotherapy
* Previous systemic therapy with severe bone marrow suppression or hematological diseases
* Hip-replacements
* Contraindications to MRI-scan

Primary outcomes:
measure: Rate of PIFs
timeFrame: 1 year
Secondary outcomes:
measure: Rate of symptomatic PIFs
timeFrame: after 1 and 3 year
measure: Rate of toxicity from standard organs at risk (OAR)
timeFrame: after 1 and 3 years
measure: Predictive and prognostic biomarkers
timeFrame: Pre-treatment, By end of therapy (on average 30 days) and after 1 and 3 years
measure: Patient reported outcomes measures (LARS)
timeFrame: Pretreatment and at 1 and 3 years
measure: Patient reported outcome measures (FACT-BP)
timeFrame: Pretreatment and after 1 and 3 years
measure: Quality of Life measures (EORTC)
timeFrame: Pretreatment and after 1 and 3 years
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
affiliation: Experimental Clinical Oncology, AUH, And Danish Anal Cancer Group, DACG
name: Karen-Lise G Spindler, DMSc, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04457050: Effect of Hepatitis C Clearance on Insulin Resistance
Official title: Insulin Resistance and Resistin In Non-Diabetic Patients With Chronic Hepatitis C Before and After Direct-Acting Antiviral Drugs.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Insulin Resistance
Hepatitis C
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2020-07-07
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Chronic hepatitis C infection has been linked to insulin resistance, which is the essential component of metabolic syndrome and type 2 diabetes mellitus. Resistin; an adipokine, has been demonstrated to stimulate the secretion of several inflammatory factors known to play a role in the induction of insulin resistance. we investigated the changes in insulin resistance after hepatitis C clearance in the era of direct antivirals.

Detailed description: the link between hepatitis C infection and insulin resistance has been established. Insuli resistance has been linked to poor response to interferon based therapy. recently, direct acting antiviral drugs are approved for hepatitis C elimination with high potency and safety. The aim of the study is to: 1. Determine the prevalence of insulin resistance among non-diabetic patients with chronic HCV infection. 2. Explore the impact of treatment with DAAs on insulin resistance among chronic HCV infected patients. 3. Investigate the role of insulin resistance as a potential prognostic factor for the response to DAAs. 4. Explore the utility of resistin as a potential biomarker IR among HCV infected patients.

Eligibility criteria: Inclusion Criteria:

* Hepatitis C treatment-naïve;
* Non-diabetic patients.

Exclusion Criteria:

* Seropositivity for hepatitis B virus infection;
* Diabetes mellitus;
* Bbody mass index ≥ 30 Kg/M\*2;
* History of alcohol consumption;
* Endocrinopathies that may affect the glycemic homeostasis;
* Other known causes of chronic liver disease; Hepatic decompensation \[defined as history of gastrointestinal bleeding (melena and /or hematemesis), jaundice, coagulopathy, hepatic encephalopathy, and/or ascites\]; bleeding diathesis;
* Connective tissue diseases;
* Autoimmune diseases;
* Cardiac, respiratory or renal disease.
* Patient receiving immuno-modulatory therapy or drugs that affect the blood glucose levels such as steroids or beta-blockers.

Primary outcomes:
measure: Change in the insulin resistance before and after hepatitis C clearance
timeFrame: at baseline and 12 weeks after sustained virologic response
Secondary outcomes:
measure: Prevalence of insulin resistance among hepatitis C patients
timeFrame: at baseline
measure: Sustained virologic response
timeFrame: at 12 weeks after treatment
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Faculty of Medicine
Study officials:
References:
Clinical trial NCT04748250: Effect of Soy Phytoestrogens and Acupuncture on Bone Mineral Density in Female Athlete Triad at Adolescence Age
Official title: Effect of Soy Phytoestrogens and Acupuncture on Bone Mineral Density in Female Athlete Triad at Adolescence Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoporosis, Osteopenia
Keywords: female athlete triad
Lead sponsor: Badr University
Sponsor class: OTHER
First posted: 2021-02-10
Enrollment: 60
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The aim of this study to determine the effect of soy phytoestrogens and acupuncture on osteoporosis in female athlete triad at adolescence age. It is hypothesized that:

- There will be no statistical significant difference between the effects of soy phytoestrogens and acupuncture on osteoporosis in female athlete triad at adolescence age. RESEARCH QUESTION: Do soy phytoestrogens and acupuncture have an effect on bone mineral density in female athlete triad at adolescence age?

Detailed description: Many female athletes don't depend only on physical training and exercising to obtain the ideal slim and thin body. So that they follow harmful unhealthy diet to achieve the ideal body shape they are seeking. These types of diet can lead to malnutrition, menstrual disturbances, and bone loss, and these three components form a triad called female athlete triad. A limited number of studies have examined the effect of acupuncture and soy products on irregularities related to female athletes so the aim of this study is to investigate the effect of both acupuncture in line with diet modification using soy products on osteopenia in female athlete triad. Study Design: A prospective, randomized, single-blind, pre-post-test, controlled trial.

Sixty female athletes with ages ranged from 14 to 18 years, playing gymnastics and all diagnosed and referred with female athlete triad resulting in decreased bone mineral density and osteoporosis. All participants will be treated with soy products and acupuncture and will be closely followed for six months. DEXA will be used to assess bone mineral density before and after the treatment program.

Eligibility criteria: Inclusion Criteria:

All girls diagnosed with female athlete triad resulting in osteopenia

* Their age between 14-18 years old
* Their body mass index is less than 5 percent according to the gross motor chart
* All participants are gymnastics players
* All are medically stable
* They will be able to follow instructions

Exclusion Criteria:

* Marriage
* Pregnancy
* Taking any hormonal treatment
* Receiving any other form of traditional physical therapy modalities

Primary outcomes:
measure: Bone Mineral Density
timeFrame: Six months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Physical Therapy, Badr University
Study officials:
affiliation: Badr University in Cairo
name: Hend Reda, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00002050: A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
Official title: A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: Semen
Thymopentin
Leukocytes, Mononuclear
AIDS-Related Complex
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.


Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* Aerosolized pentamidine.

Patients must have the following:

* Seropositive for HIV-1 (ELISA assay) confirmed by Western blot.
* HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' PBMC on two separate occasions.
* Voluntarily sign consent.
* Patients with HIV "wasting syndrome" are allowed.

Prior Medication:

Allowed:

* Aerosolized pentamidine.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

* AIDS as defined by the CDC.
* Significant hepatic disease.
* Thrombocytopenia.
* Hypersensitivity to thymopentin.
* Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
* Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.

Patients with the following are excluded:

* AIDS as defined by the CDC.
* Significant hepatic disease.
* Thrombocytopenia.
* Hypersensitivity to thymopentin.
* Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
* Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.

Prior Medication:

Excluded within 30 days of study entry:

* Immunomodulatory or experimental therapy.
* Excluded within 90 days of study entry:
* Zidovudine (AZT).

Intravenous drug abuse.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Annandale
country: United States
facility: Immunobiology Research Institute
state: New Jersey
Study officials:
References:
Clinical trial NCT06621550: Effect of High-Intensity Interval Training Exercise on Cognitive Function of Young Adults
Official title: The Effect of High-Intensity Interval Training Exercise on Cognitive Function of Young Adults: A Pilot Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Young Healthy Adults
Keywords: Executive Functions
High Intensity Interval Training
Young Healthy Adults
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2024-10-01
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To explore the sustainability of the acute effect of High Intensity Interval Training (HIIT) on executive function in young adults.


Eligibility criteria: Inclusion Criteria:

* Young adult aged 18-40 years old
* No visionary defect or other sensory condition including uncorrected refractive defect and color blindness refraining the individual to be assessed by the tasks

Exclusion Criteria:

* With known neurological, cardiovascular, or other physical and mental conditions that limit the ability to safely participate in high-intensity interval training
* With known specific learning disabilities
* Known drug or alcohol abuse problems

Primary outcomes:
measure: Stroop task
timeFrame: From baseline to 72 hours post intervention
Secondary outcomes:
measure: Flanker Task
timeFrame: From baseline to 72 hours post intervention
measure: Trail making test (TMT)
timeFrame: From baseline to 72 hours post intervention
measure: Wisconsin Card Sorting test (WCST)
timeFrame: From baseline to 72 hours post intervention
measure: Change in accuracy as measured by the 2-back task
timeFrame: From baseline to 72 hours post intervention
Other outcomes:
Locations:
city: Hung Hom
country: Hong Kong
facility: The Hong Kong Polytechnic University
Study officials:
References:
Clinical trial NCT04544150: Gastrointestinal Manifestations Among Patients With COVID19
Official title: Gastrointestinal Manifestations in COVID-19: Symptoms and Signs and Its Impact on the Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-09-10
Enrollment: 220
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: all patients with COVID 19 infection

Brief summary: many patients with confirmed infection with COVID-19 suffer from different symptoms and signs of gastrointestinal symptoms

Detailed description: many patients with COVID1-9 infection experienced many intestinal symptoms mainly abdominal pain, vomiting, and diarrhea. This study aimed to assess the frequency of GIT manifestations among patients with COVID-19 and its impact on the outcome

Eligibility criteria: Inclusion Criteria:

* all patients with COVID19

Exclusion Criteria:

* patient refusal to participate in the study

Primary outcomes:
measure: frequency of GIT symptoms among patients with COVID-19 infection
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Al Minyā
country: Egypt
facility: Ahmed
state: Alminya
Study officials:
affiliation: Assuit University Hospitals
name: Ahmed Abu elfatth
role: PRINCIPAL_INVESTIGATOR
References:
citation: Peck-Radosavljevic M, Danese S, Hartmann D, Saftoiu A, Van Hootegem P; UEG Public Affairs Committee. COVID-19 and digestive health. United European Gastroenterol J. 2020 Jun;8(5):624-626. doi: 10.1177/2050640620927955. No abstract available.
Clinical trial NCT03804450: Magnetic Resonance Imaging (MRI) of Pulp Regeneration
Official title: Magnetic Resonance Imaging Assessment of Pulp Regeneration Following Regenerative Endodontic Procedures in Mature Teeth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pulp Necroses
Periapical Lesion
Regeneration
Keywords: Mature teeth
Necrotic teeth
REPs
Biodentine
MRI
CBCT
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2019-01-15
Enrollment: 18
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present study was conducted to test whether pulp-like tissue can be regenerated in mature teeth with closed apex? And whether the size of the apical diameter affects the success of REPs? And whether Magnetic resonance imaging (MRI) can be used to quantitatively assess the vitality of the regenerated pulp-like tissue.

Detailed description: Regenerative endodontic procedures via blood clot were done on 18 mature anterior necrotic teeth with periapical lesions. The teeth were randomly assigned into two groups according to the size of the apical diameter of the rotary files used for instrumentation.

In the test group, rotary instrumentation was done using Pro-taper Next till size X3, while in the control group, instrumentation was done till size X5.

Calcium hydroxide was used as an intracanal medication for 1-2 weeks. Calcium hydroxide was then washed away using 1.5%NaOCl, followed by induction of blood using pre-curved K-fi;e #25 2mm past the radiographic apex. Biodentine was then used as a cervical plug over the blood clot followed by resin-modified glass ionomer cement and composite resin as coronal restoration.

MRI was used to assess the vitality of the regenerated pulp-like tissue, where the signal intensity of the regenerated pulp-like tissue was measured after 3,6 and 12 months follow up and compared to the normal contralateral teeth. In addition, sensibility tests using cold test and electric pulp testing were used to assess vitality of regenerated pulp-like tissue after 3,6,9 and 12 months. Cone beam computed tomography (CBCT) was also used to assess the healing of the periapical lesion after 12 months.

Eligibility criteria: Inclusion Criteria

* Upper anterior mature teeth with single canals.
* Necrotic teeth
* Presence of periapical lesion.

Exclusion Criteria:

* Presence of systemic diseases.
* Presence of stainless steel wires o brackets
* Vital immature teeth with open apex

Primary outcomes:
measure: MRI assessment of pulp-like tissue regeneration
timeFrame: 12 months
Secondary outcomes:
measure: Healing of the periapical lesion
timeFrame: 12 months
measure: Positive pulpal response
timeFrame: 12 months
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria University
Study officials:
References: